Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer
Figure 4
In vivo activity of IgG25 and IgG28 in MiaPaCa2 orthotopic xenografts. (a) Pharmacokinetic analysis of IgG25 (empty circle) and IgG28 (full circle) following a single dose at 2 mg/kg. The straight line represents the trough level of the antibody before the next administration. (b) Tumor weight at day 35 following biweekly administration of control IgG, IgG25, and IgG28. Data, expressed in grams, represent the average of tumor weight from ten different animals ( = 10). Error bars indicate the standard error. (c) Impact of IgG treatment on metastatization: the metastatic incidence is given by the number of mice with metastases in each group. The total number of metastases counted for each group is also reported. Metastatic lesions were normally distributed in liver, spleen, stomach, diaphragm, and, in few cases, kidney tissues. Involvement of local lymph nodes was not detected. Asterisks indicate statistically significant differences with respect to the control group (Student's -test; .05)
